Alimera Sciences information

Alimera Sciences Inc.
	Alimera Sciences headquarters in Alpharetta
Company type	Public
Traded as	Nasdaq: ALIM; Russell Microcap Index component
Industry	Pharmaceutical company; Health care; Biotechnology;
Founded	2003; 21 years ago
Headquarters	Alpharetta, Georgia, US
Key people	Rick Eiswirth, (president and CEO)
Products	Pharmaceuticals
Revenue	$54.1 Million(2019)
Website	www.alimerasciences.com

Alimera Sciences, Inc. is a biopharmaceutical sales company based in Alpharetta, Georgia that specializes in the commercialization and sales of prescription ophthalmic pharmaceuticals. The company's main selling focus is on diseases affecting the back of the eye, or retina.^[2] The company is the licensee for Iluvien, a fluocinolone acetonide intravitreal implant.

^ "Alimera Sciences Revenue 2009-2021 | ALIM".
^ Atlanta's Alimera Sciences IPO raises $72M Archived 2011-05-29 at the Wayback Machine, Tech Journal South, April 22, 2010. Retrieved November 22, 2010

[1] "Alimera Sciences Revenue 2009-2021 | ALIM".

[2] Atlanta's Alimera Sciences IPO raises $72M Archived 2011-05-29 at the Wayback Machine, Tech Journal South, April 22, 2010. Retrieved November 22, 2010

Alimera Sciences information

and 5 Related for: Alimera Sciences information

Alimera Sciences

Fluocinolone acetonide

New Enterprise Associates

Macular edema

PSivida